ABBOTT LABORATORIES $36.59

down -0.24


17/5/2013 07:17 PM  |  NYSE : ABT  |  Industries : Manufacturing / Medical Equipment and Supplies Manufacturing
12 Mo. Price Change : 22% - ABT has underperformed the S&P 500 by 3%

Get Trend Analysis Icon Get Trend Analysis

Partner Headlines

  1. UPDATE: Stifel Nicolaus Initiates Abbott Laboratories at Buy Post Spin

    Benzinga

  2. Hospira Stock Seesaws After Mixed Q4 Report, Guidance

    Investors Business Daily

  3. PetSmart and Other Secular Growth Picks (ACT, MYGN, PETM, HLF)

    Benzinga

  4. Weekly 52 Week Highs: ABBV, ABT, YUM, AET

    GuruFocus

  5. Abbott Spin-Off AbbVie Pays Juicy Dividend

    Investors Business Daily

  6. Should dividend investors hold on to Abbott and Abbvie following ...

    GuruFocus

  7. Pfizer Stock Hits High On Earnings, Talk Of Split

    Investors Business Daily

  8. Amgen Q4 Sales, 2013 Guidance Modestly Beat Estimates

    Investors Business Daily

  9. Med Stocks Moving: Novartis, Map, Celgene, Abbott

    Investors Business Daily

  10. Futures Mixed On Q4 Reports; Google, Cree Move Higher

    Investors Business Daily

  11. Benzinga Market Primer: Wednesday, January 23

    Benzinga

  12. US Stock Futures Flat Ahead Of McDonald's Earnings

    Benzinga

  13. Earnings Scheduled For January 23, 2013

    Benzinga

  14. Stocks To Watch For January 23, 2013

    Benzinga

  15. Reconsidering Abbott Labs (ABT) And AbbVie (ABBV)

    GuruFocus

  16. AbbVie, Abbott Spinoff, Starts Life Near Top of Pharma Industry's ...

    YCharts

  17. UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on ...

    Benzinga

  18. Pharma Flop: Story Behind Merck's Failed Cholesterol Pill

    YCharts

  19. 4 Health Care ETFs Your Broker Forgot to Mention

    Benzinga

  20. Pfizer's Anti-Rheumatoid Arthritis Pill, Potential Blockbuster, ...

    YCharts

  21. Three Actionable Trading Ideas Right Now

    Benzinga

  22. Abbott Spinoff AbbVie: Clumsy Name Least of Its Challenges

    YCharts

  23. UPDATE: BMO Capital Markets Initiates Abbott Laboratories at ...

    Benzinga

  24. AbbVie Spinoff Brings New Megacap Pharma To NYSE

    Investors Business Daily

  25. Stocks Hitting 52-Week Lows

    Benzinga

  26. Benzinga's Top Initiations

    Benzinga

  27. Why Cooperman and Price Are Betting on Boston Scientific's Turnaround

    GuruFocus

  28. Abbott Laboratories (ABT) Dividend Stock Analysis

    GuruFocus

  29. Failure City: Pharma Eats Up R&D Budgets Trying to Make Drugs to ...

    YCharts

  30. Abbott Laboratories: Quality Dividend Aristocrat for Long Term ...

    GuruFocus

  31. My Best Dividend Aristocrat Growth Picks for 2013

    GuruFocus

  32. Dividend Stocks I Purchased Over the Past Two Months

    GuruFocus

  33. Abbott to Offer New Testosterone Test for Measurement at Low Levels

    Benzinga

  34. Clinical-Trial Flops Hurt AstraZeneca, Lilly, But Bolster Abbott

    YCharts

  35. Abbott Declares $0.14/Share Qtr. Dividend, Says Spinoff AbbVie ...

    Benzinga

  36. Stocks Open Firm But Reverse Lower On Fiscal Worries

    Investors Business Daily

  37. AstraZeneca, Lilly Arthritis Drugs Flop In Trials

    Investors Business Daily

  38. Benzinga's M&A Chatter for Tuesday December 11, 2012

    Benzinga

  39. 100 Most Sold Stocks by Famous Investment Gurus

    GuruFocus

  40. Sucampo Receives $15M Milestone Payment from Abbott for AMITIZA

    Benzinga

  41. Bristol-Myers, Abbott Announce Results from Phase 2 Multiple ...

    Benzinga

  42. The Secret Ingredient of Dividend Growth Stocks

    GuruFocus

  43. Stem Cell Research Gets Boost From New Cell Bank

    Investors Business Daily

  44. My Best Healthcare Stock Picks For 2013 | Last Year's Picks Gained ...

    GuruFocus

  45. Pfizer, Stock Rising on Cost Cuts, Plans More Staff Layoffs

    YCharts

  46. Abbott Board Approves Separation of AbbVie, Declares Special ...

    Benzinga

  47. Gilead Hep C Drug Meets Expectations In Phase 3 Trial

    Investors Business Daily

  48. Becton, Dickinson and Co. (BDX) Dividend Stock Analysis

    GuruFocus

  49. S&P Reiterates Bullish View on Health Care ETFs

    Benzinga

  50. Johnson & Johnson (JNJ) Dividend Stock Analysis

    GuruFocus

  51. Big Pharma Gains Another Foe on Pay-to-Delay Deals: 31 State A.G.s ...

    YCharts

  52. Abbott Offers Details on Phase 3 Hep C Program

    Benzinga

  53. Gilead Hits High On Drug Data

    Investors Business Daily

  54. Gilead Stock Pops On Hepatitis C Drug Results

    Investors Business Daily

  55. Gilead Stock Pops On Hepatitis C Drug Results

    Investors Business Daily

  56. Abbott Announces Results of Analysis Exploring the Use of HUMIRA

    Benzinga

  57. Johnson & Johnson is Undervalued - Here's Why

    GuruFocus

  58. These 5 Stocks Are Most Hated by Big Investors

    GuruFocus

  59. Perrigo Stock Dives After Q1 Sales Miss Estimates

    Investors Business Daily

  60. Take an Out-of-Work Drug Rep to Lunch: More Big Pharma Layoffs

    YCharts

  61. Myriad Genetics Stock Hits High On Earnings Beat

    Investors Business Daily

  62. Abbott Laboratories (ABT) Chairman and CEO Miles D White sells ...

    GuruFocus

  63. Abbott Laboratories (ABT) Chairman and CEO Miles D White sells ...

    GuruFocus

  64. Abbott Laboratories (ABT) Chairman and CEO Miles D White sells ...

    GuruFocus

  65. Abbott Labs Raises $14.7B in a Six-Part Bond Offering

    Benzinga

  66. A Peek Into The Market Before The Trading Starts

    Benzinga

  67. Abaxis, Abbott in Distribution Agreement

    Benzinga

  68. Highly Confidential Attorneys' Eyes Only: Abbott Email, HIV ...

    YCharts

  69. Abbott's ALK Test is Now Available in Europe

    Benzinga

  70. Dividends versus Homemade Dividends

    GuruFocus

  71. Gilead Profit, Sales Beat Estimates As HIV Drugs Boom

    Investors Business Daily

  72. Abbott Receives Positive Opinion from CHMP for HUMIRA Use in ...

    Benzinga

  73. Abbott's Kidney Drug, a Potential Blockbuster, Suffers Setback: ...

    YCharts

  74. Stocks Fall In Early Afternoon On Weak Google Profit

    Investors Business Daily

  75. Pharmaceutical Stocks Are All-of-a-Sudden Hot Again: Read About ...

    YCharts

  76. Baxter Q3 Sales Light; Medtech Stocks Fall

    Investors Business Daily

  77. Benzinga's Top Downgrades

    Benzinga

  78. Apricus Biosciences Receives $2.5M Payment From Abbott Laboratories

    Benzinga

  79. Exchange rate hits Abbott Q3

    Investors Business Daily

  80. Abbott Labs Beats Earnings Views; HCV Trial Launched

    Investors Business Daily

  81. Don't Call it Bribery  And Whatever it Was, Abbott Stopped Doing ...

    YCharts

  82. Earnings Scheduled For October 17, 2012

    Benzinga

  83. Earnings Preview: Abbott Laboratories

    Benzinga

  84. Abbott Laboratories Traders Hopeful Ahead of Earnings

    By SchaeffersResearch

  85. Good marks for hep-C drugs

    Investors Business Daily

  86. Abbott, Bristol-Myers Pop On Hepatitis C Drug News

    Investors Business Daily

  87. Pharma's March Into Emerging Markets Hits Yet Another Rough Spot

    YCharts

  88. 10 Dividend Stocks That Gave Me a 20%+ Annualized Return

    GuruFocus

  89. How to be a Dividend Winner

    GuruFocus

  90. Part I: Must Know ETFs For Q3 Earnings

    Benzinga

  91. Big Pharma's Push Into Emerging Markets Meets More Resistance: ...

    YCharts

  92. All Investments Carry Risk

    GuruFocus

  93. The 20 Biggest Healthcare Dividend Payer

    GuruFocus

  94. Abbott's HUMIRA Receives U.S. FDA Approval

    Benzinga

  95. Thanks Mostly to J&J, Glaxo and Abbott, Feds and States Collecting ...

    YCharts

  96. Stocks Delivering the Dividend Dream

    GuruFocus

  97. Celgene's Drug Pipeline News Soothes Investor Worries

    Investors Business Daily

  98. The 10 Best and Cheapest S&P 500 Dividend Aristocrats

    GuruFocus

  99. UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on ...

    Benzinga

  100. Race For Next Hepatitis C Drug Gets Tighter

    Investors Business Daily
People viewing ABT also viewed: , , , , , ,
Marketplace
Trading Center